利妥昔单抗治疗难治性系统性红斑狼疮的短期疗效与安全性:英国群岛狼疮评估组生物制剂登记研究结果
纳入2010年9月至2015年9月英国群岛狼疮评估组生物制剂登记中开始生物制剂治疗的270例难治性SLE患者,其中261例使用利妥昔单抗。6个月时49%的患者达到应答,BILAG和SLEDAI-2K评分均显著下降,糖皮质激素用量减少,26例(10%)发生严重感染,多集中于输注后前3个月。
要点
- 利妥昔单抗治疗难治性SLE,6个月应答率为49%。
- BILAG评分中位数从15降至3,SLEDAI-2K从8降至4。
- 严重感染发生率为10%,输注后前3个月更常见。
核心结论
- 利妥昔单抗在难治性SLE患者中安全,且与疾病活动度改善及糖皮质激素用量减少相关。
- 输注后早期警惕感染对进一步改善治疗风险获益很重要。
研究设计与样本
- 研究分析了2010年9月至2015年9月在英国群岛狼疮评估组生物制剂登记中开始生物制剂治疗的270例难治性SLE患者,其中261例使用利妥昔单抗。
- 分析了基线特征、疾病活动度(BILAG 2004/SLEDAI-2K)及随访期间感染率,应答定义为6个月时所有A和B BILAG评分消失至≤1个B评分且其他器官系统无新发A/B评分。
- 6个月时68%的患者有应答率数据。
主要发现
- 基线时250例(93%)患者使用糖皮质激素,中位口服剂量为每日10 mg(IQR 5-20 mg)。
- BILAG评分中位数(IQR)从基线15(10-23)降至6个月时3(2-12)(P < 0.0001)。
- SLEDAI-2K中位数(IQR)从8(5-12)降至4(0-7)(P < 0.001)。
- 49%的患者达到应答。
- 糖皮质激素用量减少至6个月时中位剂量7.5 mg(IQR 5-12 mg)(P < 0.001)。
关键数值与推荐
- 应答定义为6个月时所有A和B BILAG评分消失至≤1个B评分且其他器官系统无新发A/B评分。
- 6个月时49%的患者达到应答。
- BILAG评分中位数从基线15降至6个月时3(P < 0.0001)。
- SLEDAI-2K中位数从8降至4(P < 0.001)。
- 糖皮质激素中位剂量从基线每日10 mg降至6个月时每日7.5 mg(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK and to explore short term efficacy and infection rates associated with rituximab (RTX) use. METHODS: Patients commencing biologic therapy for refractory SLE and who consented to join BILAG-BR were analysed. Baseline characteristics, disease activity (BILAG 2004/SLEDAI-2K) and rates of infection over follow-up were analysed. Response was defined as loss of all A and B BILAG scores to ⩽ 1 B score with no new A/B scores in other organ systems at 6 months. RESULTS: Two hundred and seventy SLE patients commenced biologic therapy from September 2010 to September 2015, most commonly RTX (n = 261). Two hundred and fifty (93%) patients were taking glucocorticoids at baseline at a median [interquartile range (IQR)] oral dose of 10 mg (5-20 mg) daily. Response rates at 6 months were available for 68% of patients. The median (IQR) BILAG score was 15 (10-23) at baseline and 3 (2-12) at 6 months (P < 0.0001). The median (IQR) SLEDAI-2K reduced from 8 (5-12) to 4 (0-7) (P < 0.001). Response was achieved in 49% of patients. There was also a reduction in glucocorticoid use to a median (IQR) dose of 7.5 mg (5-12 mg) at 6 months (P < 0.001). Serious infections occurred in 26 (10%) patients, being more frequent in the first 3 months post-RTX therapy. A higher proportion of early infections were non-respiratory (odds ratio = 1.98, 95% CI: 0.99, 3.9; P = 0.049). CONCLUSION: RTX is safe and is associated with improvement in disease activity in refractory SLE patients with concomitant reductions in glucocorticoid use. Early vigilance for infection post-infusion is important to further improve treatment risks and benefits.
引用
- McCarthy EM, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford). 2018. PMID: 29216396. doi:10.1093/rheumatology/kex395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。